摘要
BACKGROUND Inflammatory bowel disease(IBD)may limit physical activity due to intestinal or extraintestinal manifestations,fatigue,or exercise perception.We sought to evaluate the influence of IBD diagnosis on exercise and sports participation in a pediatric population.We compared patient-reported and parent-reported perspectives.AIM To evaluate the influence of IBD diagnosis on exercise and sports participation in a pediatric population.METHODS Consecutive IBD outpatients(aged 10-18 years)and their parents completed parallel voluntary surveys.A validated,patient-reported functional activity scale,the Hospital for Special Surgery Pediatric Functional Activity Brief Scale(HSS Pedi-FABS)was used to assess children’s activity levels.RESULTS There were 149 completed surveys(75%response rate)with mean participant age of 16.5 years[standard deviation(SD)=4.0]and mean age at IBD diagnosis of 11.8 years(SD=3.4).Most patients(77%)were diagnosed within 12 mo of symptom onset.Current athletic participation was reported in 65%across 65 sports.Participation was greatest before(40%)rather than after(32%)IBD diagnosis,with no reported change in 28%.IBD negatively impacted play/performance in 45%but did not change play/performance in 44%.IBD treatment improved patients’desire to exercise(70%)and subjective capacity for aerobic exercise(72%).Patients and parents agreed that IBD subjects demonstrate normal capacity for aerobic exercise(0.40,95%CI:0.22-0.58)and that treatment improved both participatory desire(0.33,95%CI:0.12-0.54)and capacity for aerobic exercise(0.52,95%CI:0.31-0.71).Almost all(99%)viewed exercise as healthy,and most encouraged its practice.IBD patients demonstrated normal mean HSS Pedi-FABS scores.CONCLUSION After pediatric IBD diagnosis,most patients continue exercise and sports,with mean activity levels comparable to American youth.Treatment positively impacts participatory desire and aerobic capacity.Patients favor the role of exercise in IBD.
BACKGROUND Inflammatory bowel disease(IBD) may limit physical activity due to intestinal or extraintestinal manifestations, fatigue, or exercise perception. We sought to evaluate the influence of IBD diagnosis on exercise and sports participation in a pediatric population. We compared patient-reported and parent-reported perspectives.AIM To evaluate the influence of IBD diagnosis on exercise and sports participation in a pediatric population.METHODS Consecutive IBD outpatients(aged 10-18 years) and their parents completed parallel voluntary surveys. A validated, patient-reported functional activity scale,the Hospital for Special Surgery Pediatric Functional Activity Brief Scale(HSS Pedi-FABS) was used to assess children’s activity levels.RESULTS There were 149 completed surveys(75% response rate) with mean participant age of 16.5 years [standard deviation(SD) = 4.0] and mean age at IBD diagnosis of11.8 years(SD = 3.4). Most patients(77%) were diagnosed within 12 mo of symptom onset. Current athletic participation was reported in 65% across 65 sports. Participation was greatest before(40%) rather than after(32%) IBD diagnosis, with no reported change in 28%. IBD negatively impacted play/performance in 45% but did not change play/performance in 44%. IBD treatment improved patients’ desire to exercise(70%) and subjective capacity for aerobic exercise(72%). Patients and parents agreed that IBD subjects demonstrate normal capacity for aerobic exercise(0.40, 95%CI: 0.22-0.58) and that treatment improved both participatory desire(0.33, 95%CI: 0.12-0.54) and capacity for aerobic exercise(0.52, 95%CI: 0.31-0.71). Almost all(99%) viewed exercise as healthy, and most encouraged its practice. IBD patients demonstrated normal mean HSS Pedi-FABS scores.CONCLUSION After pediatric IBD diagnosis, most patients continue exercise and sports, with mean activity levels comparable to American youth. Treatment positively impacts participatory desire and aerobic capacity. Patients favor the role of exercise in IBD.
基金
the National Institute of Health/National Institute of Diabetes and Digestive and Kidney Diseases,No.5P30DK34854
